New ulcerative colitis drug takes first step: safety check in healthy volunteers
NCT ID NCT07505030
First seen Apr 12, 2026 · Last updated May 02, 2026 · Updated 3 times
Summary
This early-stage study tests a new drug called LYNC-101 in 50 healthy adults to see if it is safe and how the body processes it. The drug is being developed for ulcerative colitis, a chronic bowel disease. Participants will receive either the drug or a placebo by IV, in single or multiple doses. This study does not aim to treat any disease, only to gather safety information for future research.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UC - ULCERATIVE COLITIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
CMAX Clinical Research Pty Ltd
Adelaide, South Australia, 5000, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.